The endocannabinoid system (ECS) is related to neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and vascular dementia. Preclinical studies show that the ESC is linked to neuropathology, neurotransmission, as well as neurobiology associated with dementia. It also has a vital role in regulating bodily functions.
Aliments linked to dementia are increasing in prevalence among the aging in societies worldwide. While there is no cure-all treatment, the treatment that is available is a costly burden added to the physical, mental, and emotional hardships faced by those diagnosed as well as family and friends.
Here is the full scientific article if you wish to download it.
Clinical trials have shown that cannabinoid receptors that are targeted by “receptor agonists, antagonists and cannabidiol” may be an effective treatment for the symptoms related to dementia. Though more human studies need to be done to explore the depth of the effectiveness of cannabis treatments. This is positive and promising, however, side effects still need to be addressed and studied further.
This study states that “Because of their broad impact on neurotransmission through retrograde signaling and involvement in inflammation, endocannabinoids have been suggested as modulators of various neurodegenerative diseases”.
CBD was attributed to being an “antioxidant as well as anti-apoptotic compound reduced DNA fragmentation, lipid peroxidation, the production of reactive oxygen species, the levels of key enzymes for apoptosis as well as the intracellular calcium”.
Cannabinoids are involved in the neurodegenerative disease makeup. It is being studied more in-depth to determine if the non-psychoactive cannabinoid CBD (cannabidiol) may actually slow down the process in Alzheimer’s disease linked directly on the cognitive decline. Controlled cannabis may, in fact, be the future of a combined treatment for Alzheimer’s disease as well as other neurodegenerative disorders.